Select which category you are interested in:
Novartis’s rare cancer drug is launched in the UK
Pharmatimes have reported that Novartis have launched their new drug Jakavi which means for the first time patients in the UK with a rare form of blood cancer will now have access to this targeted therapy
Jakavi (ruxolitinib) is a first-in-class JAK 1 and JAK 2 inhibitor, and is now available to treat patients in the UK with disease-related enlarged spleen or various forms of myelofibrosis, which affects around 0.34-0.76 people in every 100,000.
Myelofibrosis is a rare, potentially life-threatening blood cancer characterised by bone marrow failure, enlarged spleen and debilitating symptoms including extreme fatigue, poor quality of life and weight loss, and shortened survival.
Jakavi received EU approval at the end of August 2012